May 2025, LAW OF “RIGHT-TO-TRY” SB535 has been approved in Montana, indicating that any patients in Montana have the right to try the Investigational drugs/devices that have completed Phase I clinical trials.

Trilingual global finance executive and strategic operator with 25 years of leadership experience across the United States, Japan, and China, spanning both public and private biopharmaceutical companies. She brings CFO-level expertise in financial strategy, capital markets, governance, and cross-border operations, and works closely with executive teams and boards to support long-term, sustainable growth while maintaining strong financial discipline, transparency, and operational excellence.

Mohan Krishnan, MS & MBA, advisor:  Over 30 years of experience in various fields, including Nuclear and Aerospace Engineering. He is a great innovator and owns several patents in Engineering; and as a lover of math, he has formulated fundamental algorithms in basic mathematics. He is a serial Entrepreneur currently building his revolutionary new startup, after having successfully exited from his 3 previous companies in 3 different fields.

Coleman Murray, Ph.D., SAB: Expert in Life Science Entrepreneurship, Automation & Biotools, Founder and COO of Ferrologix Inc. for 10 years.

Xiaoqin Ye, MD & Ph.D., SAB: Full Professor and Graduate Coordinator, Department of Physiology and Pharmacology, College of Veterinary Medicine & Interdisciplinary Toxicology Program, The University of Georgia. A top scientist in the field of women’s reproductive tract and embryo implantation.

Marcel van Duin, Ph.D., SAB: CSO of Heranova Lifesciences, CSO of Organon, VP of Ferring Pharmaceuticals, VP of Merck & Co., Head of Reproductive medicine and women’s health, Head of external innovation & emerging science. Top scientist & leader & entrepreneur in women’s health.

Fei Hong, Ph.D., SAB: 18 years in drug development, CMC, and regulatory affairs for biologics (cellular and gene therapy products, exosomes, cellular nanoparticles (CNPs)).  Experience with regulatory filings, including IND, ANDA, NDA, BLA, and FDA/EMA/ICH regulations and guidance for drug development.

Dr. Bruce Kahn is a board-certified gynecologic surgeon, professor, and accomplished women’s health researcher. With decades of experience in patient care and work on clinical trials, he specializes in treating complex gynecologic problems, including endometriosis, uterine fibroids, menopause, pelvic floor disorders, and innovative medical device development

Santosh Kesari, MD & Ph.D., board of directors: America’s top neuro-oncologist, focused on research of cancer stem cells, has developed a robust research program in regeneration medicine, brain health, and precision medicine to detect and prevent diseases. He has more than 350 publications.

Xiaoyan Sheng, Ph.D. brings over 30 years of combined experience in clinical research, drug discovery, and manufacturing. Her work spans metabolic and autoimmune diseases, neurodegenerative disorders, infertility treatments, T-cell vaccine therapy, and regenerative medicine. She holds six patents and has authored more than a dozen peer-reviewed publications. One of her patents was successfully commercialized, generating over $300 million in revenue for the company. She is a true innovator, deeply committed to advancing women’s health.